🇺🇸 FDA
Pipeline program

Atogepant

3101-312-002

Phase 3 small_molecule active

Quick answer

Atogepant for Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine) is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials